BRINZOLAMIDE-LOADED ETHO-LECIPLEX FOR EFFECTIVE OCULAR MANAGEMENT OF GLAUCOMA: D-OPTIMAL DESIGN OPTIMIZATION AND IN-VIVO EVALUATION
DOI:
https://doi.org/10.22159/ijap.2024v16i5.51259Keywords:
Brinzolamide, Etho-leciplex, Glaucoma, D-optimal design, In-vivo studyAbstract
Objective: Brinzolamide (BRZ) is an active carbonic anhydrase inhibitor adopted for glaucoma management. The limited aqueous solubility of the drug restricts its potential for ocular administration. Therefore, the aim of this investigation was to design a nanocarrier system called Etho-Leciplex (Etho-LPs) for the delivery of BRZ.
Methods: Etho-LPs were fabricated by a simple one-step technique and then optimized by D-optimal design employing Phospholipon®90G (PC): surfactant ratio and surfactant type (Cetyl Trimethyl Ammonium Bomide (CTAB)& Searylamine; SA) as independent variables, whereas the dependent variables were Entrapment Efficiency (EE%), Particle Size (PS), Polydispersity Index (PDI), and Zeta Potential (ZP). Design Expert® statistically suggested the optimum Etho-LP which consisted of PC: Surface Active Agent (SAA) molar ratio (X1) of 1:1.27and mixture of CTAB and SA (X2) in 1:1 molar ratio.
Results: The optimum Etho-LPs particles had spherical morphology, and EE% of 91.12±0.2 %, PS of 76.21± 1.21 nm, PDI of 0.421±0.001 and ZP of 35.88 ±0.10 mV. The in-vitro release study results demonstrated that BRZ is rapidly liberated from the optimum Etho-LPs compared to BRZ-suspension. Further, the optimum Etho-LP showed good mucoadhesive properties besides potential safety on rabbits’ eyes tissues. The optimum Etho-LP was found to enhance the ocular bioavailability of drug in rabbits’ eyes relative to the BRZ suspension. In addition, histopathological assessment indicated the safety of BRZ-loaded Etho-LPs.
Conclusion: Overall, the obtained outcomes indicated the effectiveness of employing Etho-LPs for the treatment of glaucoma.
Downloads
References
Shukr MH, Ismail S, El-hossary GG, and El-shazly AH. (2021) Design and evaluation of mucoadhesive in situ liposomal gel for sustained ocular delivery of travoprost using two steps factorial design. J Drug Deliv Sci Technol. 2021; 1(61): 102333. doi:10.1016/j.jddst.2021.102333.
Maier PC, Funk J, Schwarzer G, Antes G, and Falck-ytter YT. Treatment of ocular hypertension and open angle glaucoma : meta-analysis of randomised controlled trials, BMJ.2005;16;331(7509):134. doi: 10.1136/bmj.38506.594977.E0. Epub 2005 Jul 1.
Bengtsson B, Leske MC, Hyman L, and Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2006;114 (2): 205–209. doi:10.1016/j.ophtha.2006.07.060.
Conlon R, Saheb H, and Ahmed IIK.Glaucoma treatment trends : a review, Can J Ophthalmol. 2016;52(1): 114–124. doi:10.1016/j.jcjo.2016.07.013.
Lindén C, and Alm A. Prostaglandin analogues in the treatment of glaucoma. Drugs Aging. 1999; 14(5): 387–398.
Tejwani S, Machiraju P, Padmanabhan, A et al.Treatment of glaucoma by prostaglandin agonists and beta- blockers in combination directly reduces pro-fibrotic gene expression in trabecular meshwork. JCell Mol Med. 2020;24(9):5195-5204. doi: 10.1111/jcmm.15172. Epub 2020 Apr 8.
Supuran CT, Saleh A, AltamimiA, and Carta F. Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review. Expert Opin. 2019; 29(10): 781–792. doi:10.1080/13543776.2019.1679117.
Nocentini A, and SupuranCT.Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review. Expert Opin Ther Pat.2019; 10:805–815. doi:10.1080/13543776.2019.1665023.
Jain Neelam, Verma A, and Jain Neeraj. Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma : intraocular pressure measurement in white albino rabbits, Drug Deliv.2020; 27(1): 888–899. doi:10.1080/10717544.2020.1775726.
Yadav,KS, Rajpurohit R, and Sharma S. Glaucoma : Current treatment and impact of advanced drug delivery systems. Life Sci. 2019; 15(221):362-376. doi: 10.1016/j.lfs.2019.02.029. Epub 2019 Feb 21.
Winum J, Casini A, Mincione F, Starnotti M, Montero, J, and Supuran, CT. Carbonic anhydrase inhibitors : N - ( p -sulfamoylphenyl ) D - glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits, Bioorg Med Chem Lett. 2004; 5:14(1):225-9. doi: 10.1016/j.bmcl.2003.09.063.
SulathaVB, Krishna R, Akshay HT. Brinzolamide-induced eye discharge: a rare entity. Asian J Pharm Clin Res. 2016;9(2):1-2.
GohilR, Patel A, Pandya T, and Dharamsi A. Optimization of brinzolamide loaded microemulsion using formulation by design approach : characterization and in-vitro evaluation. Curr Drug Ther.2019; 1;15(1):37-52.. doi:10.2174/1574885514666190104115802.
Zhou Y, Fang A, Wang, et al. Core-shell lipid-polymer nanoparticles as a promising ocular drug delivery system to treat glaucoma. Chinese ChemLett.2020;31(2): 494–500. doi:10.1016/j.cclet.2019.04.048.
Younes NF, Abdel-halim SA, and Elassasy AI. Solutol HS15 based binary mixed micelles with penetration enhancers for augmented corneal delivery of sertaconazolenitrate : optimization , in vitro , ex vivo and in vivo characterization, Drug Deliv. 2018; 25(1):1706-1717. doi: 10.1080/10717544.2018.1497107.
Raj VK, Mazumder RU, Madhra MO. Ocular drug delivery system: challenges and approaches. Int J Appl Pharm. 2020;12:49-57.
Younes NF, Abdel-halim SA, Elassasy Abdelhalim I and Elassasy A I. Corneal targeted Sertaconazole nitrate loaded cubosomes : preparation , statistical optimization , in vitro characterization , ex vivo permeation and in vivo studies. Int J Pharm. 2018; 20(1-2):386-397.
Abdelbary GA, Amin MM, Zakaria, MY. Ocular ketoconazole-loaded proniosomalgels : formulation , ex vivo corneal permeation and in vivo studies. Drug Deliv. 2017;24(1): 309–319. doi:10.1080/10717544.2016.1247928.
Hassan DH, Abdelmonem R, and Abdellatif MM. Formulation and characterization of carvedilol leciplex for glaucoma treatment: In-vitro, ex-vivo and in-vivo study. Pharmaceutics.2018; 10(4):197. doi:10.3390/pharmaceutics10040197.
OkurNÜ, and Gökçe, EH. Lipid nanoparticles for ocular drug delivery. Int J Ophthalmic Res. 2015; 1(3):77–82. doi:10.17554/j.issn.2409-5680.2015.01.29.
Suri R, Beg S, and Kohli K. Target strategies for drug delivery bypassing ocular barriers. J Drug Deliv Sci Technol. 2020; 1(55): 101389. doi:10.1016/j.jddst.2019.101389.
Das B, Kumar, A, and Mallick S. Lipid-based nanocarriers for ocular drug delivery : An updated review. J Drug Deliv Sci Technol. 2022;76: 103780. doi:10.1016/j.jddst.2022.103780.
Sánchez-lópez E, Espina M, Doktorovova S, SoutoEB, and García ML. Lipid nanoparticles ( SLN , NLC ): Overcoming the anatomical and physiological barriers of the eye – Part II - Ocular drug-loaded lipid nanoparticles. Eur J Pharm Biopharm. 2016;110: 58–69. doi:10.1016/j.ejpb.2016.10.013.
Albash R, Abdellatif MM, Hassan M, and Badawi NM. Tailoring terpesomes and leciplex for the effective ocular conveyance of moxifloxacin hydrochloride (Comparative assessment): In-vitro, ex-vivo, and in-vivo evaluation. Int J Nanomedicine. 2021; 16: 5247–5263. doi:10.2147/IJN.S316326.
Neeraj J, Anurag v, Neelam J. Preformulation studies of niosomal gel containing dipivefrin hydrochloride for antiglaucomatic activity. Int J PharmPharma Sci.2024:16(2):1-7.
Pankaj k J, Shikha K, Tapash C. Lipid-polymer hybrid nanocarriers as a novel drug delivery platform. Int J Pharm Pharm sci. 2022: 12(4):1-12.
Abdellatif MM, Josef M, El-nabarawiMA, and Teaima M. Sertaconazole-nitrate-loaded leciplex for treating keratomycosis : optimization using d-optimal design and in vitro , ex vivo , and in vivo studies. Pharmaceutics. 2022: 14(10):2215. doi: 10.3390/pharmaceutics14102215.
Date AA, Aswal V, Thamm J, and FahrA. Lecithin-based novel cationic nanocarriers ( leciplex ) I : fabrication , characterization and evaluation preliminary communication, Nanomedicine. 2011;6(8): 1309–1325.
Dhawan VV, Joshi GV, and Jain AS. Apoptosis induction and anti-cancer activity of leciplex formulations. Cell Oncol. 2014;37(5): 339–351. doi:10.1007/s13402-014-0183-7.
Shah SM, Ashtikar, M, Jain, AS, et al. LeciPlex ,invasomes , and liposomes : A skin penetration study, Int J Pharm. 2015;25(1-2):391-403. doi: 10.1016/j.ijpharm.2015.05.042. Epub 2015 May 19.
Date AA, Nagarsenker MS, Patere S, et al. Lecithin-based novel cationic nanocarriers ( leciplex ) ii : improving therapeutic efficacy of quercetin on oral administration. Mol Pharm.2011;8(6):716–726.
ElmowafyM, Shalaby K, Alruwaili NK. et al. EthoLeciplex : a new tool for effective cutaneous delivery of minoxidil, Drug Dev Ind Pharm. 2022; 48(9):457-469. doi: 10.1080/03639045.2022.2124261. Epub 2022 Sep 22.
Elela MMA, Elkasabgy NA, and Basalious EB. Bio-shielding in situ forming gels ( BSIFG ) loaded with lipospheres for depot injection of quetiapine fumarate : in vitro and in vivo evaluation, AAPS PharmSciTech.2017;18(8): :2999-3010. doi:10.1208/s12249-017-0789-y.
Taweel MM, El Aboul-einien, MH, Kassem, MA, and Elkasabgy, NA. Intranasal zolmitriptan-loaded bilosomes with extended nasal mucociliary transit time for direct nose to brain delivery. Pharmaceutics. 2021; 13(11):1828. doi: 10.3390/pharmaceutics13111828.
Albash R, Badawi NM, Hamed MIA. et al. Exploring the synergistic effect of bergamot essential oil with spironolactone loaded nano-phytosomes for treatment of acne vulgaris : in vitro optimization in silico studies and clinical evaluation. Pharmaceuticals.2023;16(1):128.
Albash R, Ragaie MH, Hassab MA El, et al. Fenticonazole nitrate loaded trans-novasomes for effective management of tinea corporis : design characterization , in silico study , and exploratory clinical appraisal. Drug Deliv. 2022;29(1): 1100–1111. doi:10.1080/10717544.2022.2057619.
Zeb A, and UllahK. Development in-vitro and in-vivo evaluation of ezetimibe-loaded solid lipid nanoparticles and their comparison with marketed product, JDrug Deliv Sci. Technol.2019;1(51): 583–590. doi:10.1016/j.jddst.2019.02.026.
Zaghloul N, Hoffy NM. El Mahmoud AA, and Elkasabgy NA. Cyclodextrin stabilized freeze-dried silica / chitosan nanoparticles for improved terconazole ocular bioavailability, Pharmaceutics. 2022;14(3):470. doi: 10.3390/pharmaceutics14030470.
Abd-elsalam WH, and Elkasabgy NA. Mucoadhesive olaminosomes : A novel prolonged release nanocarrier of agomelatine for the treatment of ocular hypertension. Int J Pharm. 2019; 560: 235–245. doi:10.1016/j.ijpharm.2019.01.070.
El-naggar MM, El-nabarawi MA, Teaima MH, et al. Integration of terpesomes loaded Levocetrizine dihydrochloride gel as a repurposed cure for Methicillin-Resistant Staphylococcus aureus and in-vivo studies.Int Pharm.2023;633: 122621. doi:10.1016/j.ijpharm.2023.122621.
RoggebandR, York M, Pericoi M and Braun W. Eye irritation responses in rabbit and man after single applications of equal volumes of undiluted model liquid detergent products. Food Chem Toxicol. 2000; 38(8):727-734.
Jiang S. Chappa, AK, and Proksch JW.A rapid and sensitive LC / MS / MS assay for the quantitation of brimonidine in ocular fluids and tissues, J. Chromatogr. B Analyt Technol Biomed Life Sci. 2009;15(3):107-14. doi: 10.1016/j.jchromb.2008.11.009. Epub 2008 Nov 13.
Baneux PJ, Garner D, McIntyre HB. and Holshuh HJ. Euthanasia of rabbits by intravenous administration of ketamine. J Amer Vet Med Assoc. 1986; 189(9):1038-1039.
Fang G, Wang Q, Yang X, et al. Physicochemical and Engineering Aspects Vesicular phospholipid gels as topical ocular delivery system for treatment of anterior uveitis. Colloids Surf APhysicochem. 2021;20;627, 127187. doi:10.1016/j.colsurfa.2021.127187.
Salman M, Owida H, Njoroge W, Siddiqui A. College YBC. and Ambedkar B. Development and evaluation of cationic nanostructured lipid carriers for ophthalmic drug delivery of besifloxacin. JDrug Deliv Sci Technol. 2020; 55: 101496. doi:10.1016/j.jddst.2019.101496.
Joshny J, Hari BNV, and Devi DR. Experimental optimization of lornoxicam liposomes for sustained topical delivery.Eur J Pharm Sci. 2018;112: 38–51. doi:10.1016/j.ejps.2017.10.032.
Emad A, Salah S, Amer MS, and Elkasabgy NA. 3D nanocomposite alginate hydrogel loaded with pitavastatin nanovesicles as a functional wound dressing with controlled drug release ; preparation , in-vitro and in-vivo evaluation. J Drug Deliv Sci Technol.2022; 1;(71), 103292. doi:10.1016/j.jddst.2022.103292.
Salama A, Badran M, Elmowafy M, and Soliman GM. Spironolactone-loaded leciplexes as potential topical delivery systems for female acne : in vitro appraisal and ex vivo skin permeability studies. Pharmaceutics.2019;12(1):25. doi: 10.3390/pharmaceutics12010025.
Carbone C, Tomasello B, Ruozi B, Renis M, and Puglisi G. Optimization of PIT solid lipid nanoparticles via statistical factorial design, Eur J Med Chem. 2012; 49: 110–117. doi:10.1016/j.ejmech.2012.01.001.
Das S, Ng WK, and Tan RBH. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?,Eur J PharmSci.2012;47(1): 139–151. doi:10.1016/j.ejps.2012.05.010.
Bachu RD, Chowdhury P, Al-saedi ZHF, Karla PK. and Boddu, SHS. Ocular drug delivery barriers — role of nanocarriers in the treatment of anterior segment ocular diseases, Pharmaceutics.2018; 10(28): 1–31. doi:10.3390/pharmaceutics10010028.
Kumar N, and Mandal A. Surfactant stabilized Oil-in-Water nanoemulsion : stability , interfacial tension and rheology study for enhanced oil recovery application. Nanomaterials (Basel). 2018;13;12(10):1673. doi: 10.3390/nano12101673.
VargheseSE, Fariya MK, Rajawat GS, Steiniger F, Fahr, A, and Nagarsenker MS. Lecithin and PLGA-based self-assembled nanocomposite lecithmer : preparation characterization , and pharmacokinetic / pharmacodynamic evaluation. Drug Deliv Transl Res.2016; 6(4):342-353. doi: 10.1007/s13346-016-0314-y.
MeiZ, Liu S, Wang L, Jiang J, XuJ, and Sun D. Preparation of positively charged oil / water nano-emulsions with a sub-PIT method. JColloid Interface Sci.2011;361(2): 565–572. doi:10.1016/j.jcis.2011.05.011.
Adel IM, Elmeligy MF, Abdelrahim MEA. et al. Design and characterization of spray-dried proliposomes for the pulmonary delivery of curcumin. Int J Nanomedicine. 2021;16: 2667–2687. doi:10.2147/IJN.S306831.
ApaolazaPS, Delgado D, Pozo-rodríguez A, Gascón AR, and Solinís MÁ. A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases. IntJ Pharm. 2014; 465(1–2): 413–426. doi:10.1016/j.ijpharm.2014.02.038.
Abdel-hafez SM, Hathout RM, and Sammour OA. Tracking the transdermal penetration pathways of optimized curcumin-loaded chitosan nanoparticles via confocal laser scanning microscopy. Int J Biol Macromol.2018; 108: 753–764. doi:10.1016/j.ijbiomac.2017.10.170.
KamelR, El-Wakil NA, Abdelkhalek AA. and ElkasabgyNA.Topical cellulose nanocrystals-stabilized nanoemulgel loaded with ciprofloxacin HCl with enhanced antibacterial activity and tissue regenerative properties. J Drug Deliv Sci Technol. 2021;64:102553.
Loftsson T, Jansook P, and Stefa E. Topical drug delivery to the eye : dorzolamide, Acta Ophthalmol. 2012; 90(7):603-608. doi: 10.1111/j.1755-3768.2011.02299.x.
Mathis G. Clinical ophthalmic pharmacology and therapeutics: ocular drug delivery. Vet Opthalmol. 1999;291–297.
Vo A, Feng X, Patel D, et al.In vitro physicochemical characterization and dissolution of brinzolamide ophthalmic suspensions with similar composition. Int J Pharm. 2020; 15:588, 119761. doi:10.1016/j.ijpharm.2020.119761.
Adel IM, Elmeligy MF, Amer MS. and Elkasabgy NA. Polymeric nanocomposite hydrogel scaffold for jawbone regeneration: The role of rosuvastatin calcium-loaded silica nanoparticles. Int J Pharmaceutics: X. 2023;6:100213.
Gipson IK. Progress in retinal and eye research goblet cells of the conjunctiva : A review of recent findings. Prog Retin Eye Res. 2016; 54:49-63. doi: 10.1016/j.preteyeres.2016.04.005. Epub 2016 Apr 16.
Weng Y, Liu J, Jin S, and Guo W. Nanotechnology-based strategies for treatment of ocular disease, Acta Pharm Sin B.2017;7(3): 281–291. doi:10.1016/j.apsb.2016.09.001.
Hospital CU, Province J, Province J, and Efficient, D. Nanoparticles in the ocular drug delivery, Int J Opthalmol. 2013; 6(3): 390–396. doi:10.3980/j.issn.2222-3959.2013.03.25.
Araújo J, Gonzalez E, Egea MA, Garcia ML, and Souto EB. Nanomedicines for ocular NSAIDs : safety on drug delivery. Nanomedicine. 2009; 5(4): 394–401. doi:10.1016/j.nano.2009.02.003.
Fang G, Wang Q, Yang X, et al. X Vesicular phospholipid gels as topical ocular delivery system for treatment of anterior uveitis.Colloids Surf APhysicochem. Eng. Asp. 2021;20:627, 127187. doi:10.1016/j.colsurfa.2021.127187.
Fangueiro JF, Andreani T, Egea MA, et al. Design of cationic lipid nanoparticles for ocular delivery : Development characterization and cytotoxicity. Int J Pharm. 2014;30:461(1–2), 64–73. doi:10.1016/j.ijpharm.2013.11.025.
Alhakamy, N.A., Hosny, K.M., Aldryhim, A.Y., et al. Development and optimization of ofloxacin as solid lipid nanoparticles for enhancement of its ocular activity J Drug Deliv Sci. Technol. 2022; 72: 103373. doi:10.1016/j.jddst.2022.103373.
Published
How to Cite
Issue
Section
Copyright (c) 2024 SARA NAGEEB EL-HELALY, HAYDER A HAMMOODI, MINA I. TADROS, NERMEEN A. ELKASABGY
This work is licensed under a Creative Commons Attribution 4.0 International License.
